Trial Profile
A Multiple-dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0287 C (Insulin 287) for Subcutaneous Administration in Japanese Subjects With Type 1 Diabetes
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Dec 2021
Price :
$35
*
At a glance
- Drugs Insulin icodec (Primary) ; Insulin aspart; Insulin glargine
- Indications Type 1 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 20 Dec 2019 Status changed from active, no longer recruiting to completed.
- 20 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 21 Dec 2018 Status changed from not yet recruiting to recruiting.